Waltham, MA, October 13, 2022 – Cytel Inc., provider of quantitative insights and health data analytics to leaders in life sciences, has entered into an agreement to acquire SDS Life Science AB and SDS MedteQ AB. The move will add new global talent to Cytel’s Strategic Consulting group and bring additional expertise and capabilities for the strategic development of drugs and medical devices. As a result, sponsors will have easier access to a larger, geographically expanded pool of consulting expertise to help them get new therapies to patients faster. The acquisition furthers Cytel’s global expansion and continues the company’s journey of building a diverse, multi-disciplinary, and strategic thought partner for sponsors developing new therapeutics across the biopharma and medical technology ecosystem.
As drug development becomes more complex and competitive, pharmaceutical companies need faster and better ways to bring their therapies to market. For 35 years, Cytel’s Strategic Consulting group has pioneered advanced biostatistics, decision science, and real-world evidence capabilities that enable sponsors to optimize new therapeutic development. SDS Life Science has an equally rich heritage in biostatistics and shares Cytel’s commitment to the innovative design of clinical trials and development programs, using advanced statistical and computational approaches to improve trials for patients and sponsors.
“Cytel and SDS have a tightly aligned philosophy of excellence, a harmonious knowledge base, and proven reputations as industry leaders and strategic business partners for life sciences leadership teams,” says Cytel CEO Joshua Schultz. “By fusing our like-minded knowledge pools, we are building critical new capabilities and enhancing our offering across every dimension important for efficiently developing novel therapies including pre-clinical, real world evidence, regulatory affairs, drug development, clinical project management, biostatics and medtech.
With SDS Life Science and SDS MedteQ supporting more than 100 biomedical sponsors in Scandinavia, in addition to several multinational pharmaceutical companies, the acquisition continues Cytel’s rapid growth into new global markets.
“We are now a team that can draw on a wealth of truly global talent,” says Cytel’s Chief Medical Officer Dr Albert Kim, “This acquisition adds to the already diverse intellectual community we have at Cytel and strengthens the innovative culture we value. For our customers, this means more of the innovation and thought leadership that shapes impactful development programs, now more deeply connected and accessible across new geographies, and all delivered with our established dedication to customer collaboration.”
“We are looking forward to joining forces with Cytel and adding the capabilities of their tools to our service delivery. We’ll continue to help sponsor teams efficiently overcome their toughest challenges, and with our combined science and data-based approaches and entrepreneurial spirit, we will become greater than just the sum of our parts” states Maria Lundberg, CEO, SDS Life Science.
Anna Törner, Founder of SDS Life Sciences adds “As part of the Cytel Strategic Consulting gro
up, we will be offering services at a higher strategic level, particularly with regards to trial design, RWE and data science. This will ultimately benefit the innovative Nordic life science environment and patients”.
The transaction is subject to customary closing conditions and is expected to close this quarter.